# US 2024/0173062 A1 · Neuromodulation for metabolic conditions or syndromes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0173062 A1
- Document ID: US20240173062A1
- Status: Published application
- Kind: A1
- Application number: 18/399,851
- Filed: 2023-12-29
- Published: 2024-05-30
- Earliest claimed: 2011-12-09
- Assignees: Medtronic Ireland Manufacturing Unlimited Company
- Applicants: Medtronic Ireland Manufacturing Unlimited Company
- Inventors: Bobak Robert Azamian; Jonathan Allen Coe; Scott Bradley Vafai
- Web page: https://patentgrep.com/patent/US20240173062A1

## CPC

- A61B 18/02: by cooling, e.g. cryogenic techniques
- A61B 17/00: Surgical instruments, devices or methods (A61B18/00 takes precedence; dental tools A61C3/00; eye surgery A61F9/007; ear surgery A61F11/20)
- A61B 17/00234: {for minimally invasive surgery (A61B17/0218, A61B17/0469, A61B17/12013, A61B17/1285, A61B17/29, A61B17/320016 take precedence)}
- A61B 17/32: Surgical cutting instruments ({A61B18/042 takes precedence; suture cutters A61B17/0467;} implements for ligaturing and cutting {A61B17/122, A61B17/12; instruments for rupturing the amniotic membrane A61B17/4208; specially adapted knives for eye surgery A61F9/0133})
- A61B 18/04: by heating (by applying electromagnetic radiation A61B18/18)
- A61B 18/06: caused by chemical reaction {, e.g. moxaburners}
- A61B 18/1492: {having a flexible, catheter-like structure, e.g. for heart ablation (A61B18/1477 takes precedence)}
- A61B 18/1815: {using microwaves}
- A61B 18/20: using laser
- A61B 18/24: with a catheter (A61B18/26, A61B18/28 take precedence)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 33/30: Zinc; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61M 5/14: Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61N 1/0551: {Spinal or peripheral nerve electrodes}
- A61N 5/00: Radiation therapy (ultrasound therapy A61N7/00; devices or apparatus applicable to both therapy and diagnosis A61B6/00)
- A61N 7/00: Ultrasound therapy (lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 {; using ultrasound for introducing media into the body A61M37/0092})
- A61B 2017/00318: {Steering mechanisms}
- A61B 2017/320069: {for ablating tissue}
- A61B 2017/32007: {with suction or vacuum means}
- A61B 2018/00023: {closed, i.e. without wound contact by the fluid}
- A61B 2018/00214: {Expandable means emitting energy, e.g. by elements carried thereon}
- A61B 2018/0022: {Balloons}
- A61B 2018/00404: {Blood vessels other than those in or around the heart}
- A61B 2018/00434: {Neural system}
- A61B 2018/00529: {Liver}
- A61B 2018/00577: {Ablation}
- A61B 2018/00732: {Frequency}
- A61B 2018/00791: {Temperature}
- A61B 2018/00839: {Bioelectrical parameters, e.g. ECG, EEG}
- A61B 2018/00994: {combining two or more different kinds of non-mechanical energy or combining one or more non-mechanical energies with ultrasound}
- A61B 2018/0212: {using an instrument inserted into a body lumen, e.g. catheter}
- A61B 2018/048: {in gaseous form}
- A61B 2018/1861: {with an instrument inserted into a body lumen or cavity, e.g. a catheter}
- A61N 7/022: {intracavitary}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim 3

A method comprising:
positioning at least one therapeutic element of a neuromodulation device within a hepatic artery of a subject;
causing at least one of energy or a chemical agent to be delivered by the at least one therapeutic element to nerves surrounding the hepatic artery of the subject, wherein the at least one of the energy or the chemical agent is sufficient to ablate at least some of the nerves surrounding the hepatic artery of the subject;
positioning the at least one therapeutic element of the neuromodulation device within a renal artery; and
causing the at least one of energy or the chemical agent to be delivered by the at least one therapeutic element to nerves surrounding the renal artery, wherein the at least one of the energy or the chemical agent is sufficient to ablate at least some of the nerves surrounding the renal artery.

### Claim 4 (depends on 3)

The method of claim 3, wherein the renal artery comprises a first renal artery, the method further comprising:
positioning the at least one therapeutic element of the neuromodulation device within a second renal artery; and
causing the at least one of energy or the chemical agent to be delivered by the at least one therapeutic element of the neuromodulation device to nerves surrounding the second renal artery, wherein the at least one of the energy or the chemical agent is sufficient to ablate at least some of the nerves surrounding the second renal artery.

### Claim 5 (depends on 3)

The method of claim 3, wherein:
the nerves surrounding the hepatic artery comprise sympathetic nerves of a hepatic plexus, and
the nerves surrounding the renal artery comprise sympathetic nerves surrounding the renal artery.

### Claim 6 (depends on 3)

The method of claim 3, wherein causing at least one of energy or the chemical agent to be delivered by the at least one therapeutic element comprises causing energy to be delivered by the at least one therapeutic element, and wherein the energy comprises at least one of radiofrequency energy, high-intensity focused ultrasound energy, low-intensity focused ultrasound energy, electroporation energy, ionizing energy, cryogenic energy, or microwave energy.

### Claim 7 (depends on 3)

The method of claim 3, wherein causing at least one of energy or the chemical agent to be delivered by the at least one therapeutic element comprises causing the chemical agent to be delivered by the at least one therapeutic element, and wherein the chemical agent comprises at least one of a muscarinic receptor agonist, an anticholinesterase agent, a nicotinic receptor agonist, a nicotine receptor antagonist, a neurotoxin, an alcohol, guanethidine, or zinc sulfate.

### Claim 8 (depends on 3)

The method of claim 3, wherein ablating at least some of the nerves surrounding the hepatic artery and ablating at least some of the nerves surrounding the renal artery treats hypertension.

### Claim 9 (depends on 3)

The method of claim 3, wherein:
positioning the at least one therapeutic element within the hepatic artery comprises intravascularly advancing the at least one therapeutic element into the hepatic artery; and
positioning the at least one therapeutic element within the renal artery comprises intravascularly advancing the at least one therapeutic element into the renal artery.

### Claim 10 (depends on 9)

The method of claim 9, further comprising accessing vasculature of the subject via a femoral access point.

### Claim 11 (depends on 9)

The method of claim 9, further comprising accessing vasculature of the subject via a radial access point.

### Claim 12 (depends on 3)

The method of claim 3, wherein causing at least one of energy or the chemical agent to be delivered by the at least one therapeutic element comprises causing at least one of energy or the chemical agent to be preferentially delivered by the at least one therapeutic element to sympathetic nerves surrounding the hepatic artery.

### Claim 13 (depends on 12)

The method of claim 12, wherein causing at least one of energy or the chemical agent to be preferentially delivered by the at least one therapeutic element to sympathetic nerves surrounding the hepatic artery comprises causing the at least one therapeutic element to deliver the at least one of energy or the chemical agent in a proximal portion of the hepatic artery.

### Claim 14 (depends on 13)

The method of claim 13, wherein the proximal portion of the hepatic artery comprises a common hepatic artery.

### Claim 15 (depends on 3)

The method of claim 3, wherein the neuromodulation device is configured to exert a contact force by the at least one therapeutic element against a wall of the hepatic artery of about 1 g/mm2 to about 500 g/mm2.

### Claim 16 (depends on 3)

The method of claim 3, wherein the neuromodulation device comprises a catheter comprising a distal portion configured to bend with a bend radius of less than about 10 mm.

### Claim 17 (depends on 3)

The method of claim 3, wherein the hepatic artery comprises at least one of a common hepatic artery, a proper hepatic artery, a right hepatic artery, or a left hepatic artery.

### Claim 18 (depends on 3)

The method of claim 3, wherein the hepatic artery comprises a common hepatic artery.
